4//SEC Filing
HAMED KAMAL 4
Accession 0000950170-23-048440
CIK 0001701108other
Filed
Sep 14, 8:00 PM ET
Accepted
Sep 15, 5:47 PM ET
Size
5.8 KB
Accession
0000950170-23-048440
Insider Transaction Report
Form 4
HAMED KAMAL
Chief Medical Officer
Transactions
- Sale
Common Stock
2023-09-13$1.27/sh−39,496$50,160→ 576,461 total
Footnotes (2)
- [F1]The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units ("RSUs") that were granted to the Reporting Person on September 12, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement and (ii) performance-based restricted stock units ("PSUs") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a "sell to cover" provision included in the PSU Agreement.
- [F2]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001946366
Filing Metadata
- Form type
- 4
- Filed
- Sep 14, 8:00 PM ET
- Accepted
- Sep 15, 5:47 PM ET
- Size
- 5.8 KB